Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : executive sold shares before drug data manipulation made public

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/18/2019 | 06:09pm EDT
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring near Washington

VIENNA (Reuters) - An unnamed Novartis executive sold 925,400 Swiss francs (778,665 pounds) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated.

Novartis announced the stock sale by an executive member of the board of directors or a member of the executive committee in a Swiss stock exchange filing dated July 19. The sale was first reported by Swiss newspaper SonntagsZeitung on Sunday.

A Novartis spokesman told Reuters, "As is usual in such cases, the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information."

The sale was made after the company had informed the FDA about the data manipulation but before the FDA announced it publically on Aug 6.

Shares in Novartis fell almost 3 percent the day after the FDA announcement.

The FDA said this month that Novartis notified regulators in June - more than a month after Zolgensma had been approved - that some of the early testing data had been manipulated.

The company had been aware of the problems for as long as two months before the drug's U.S. approval, the FDA said, and Novartis could face criminal or civil penalties.

Novartis said this month that it learned of allegations of data manipulation in mid-March and finished a preliminary investigation into the allegations in early May, confirming data discrepancies and raising data integrity concerns.

The data was used to illustrate comparability between an early version of Zolgensma and the later version of the treatment, which was manufactured using a different process.

The FDA said it does not believe that the manipulation impacts the safety or testing surrounding the version of the drug, which treats spinal muscular atrophy (SMA), the leading genetic cause of death in infants.

(Reporting by Francois Murphy; Editing by Alexandra Hudson)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
09/18NOVARTIS : Sandoz Halting Ranitidine Distribution
DJ
09/18NOVARTIS : halts distribution of its Zantac versions amid probe into impurities
RE
09/18NOVARTIS : Cosentyx positive 16-week PREVENT results advance potential new indic..
AQ
09/17NOVARTIS : Initiation of Novartis Entresto in-hospital included in the new ACC E..
AQ
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) -2-
DJ
09/17NOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) Positive 16-week Prevent Results A..
DJ
09/16NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
AQ
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
DJ
More news
Financials (USD)
Sales 2019 47 014 M
EBIT 2019 13 827 M
Net income 2019 10 117 M
Debt 2019 17 463 M
Yield 2019 3,45%
P/E ratio 2019 18,5x
P/E ratio 2020 20,2x
EV / Sales2019 4,56x
EV / Sales2020 4,21x
Capitalization 197 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,57  $
Last Close Price 86,02  $
Spread / Highest target 24,9%
Spread / Average Target 9,94%
Spread / Lowest Target -5,23%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS15.46%197 665
JOHNSON & JOHNSON1.05%344 174
ROCHE HOLDING LTD.14.65%241 967
MERCK AND COMPANY8.65%212 562
PFIZER-16.66%201 220
NOVO NORDISK AS15.58%121 196